Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,403 Shares

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 4,403 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $11.89, for a total value of $52,351.67. Following the sale, the chief executive officer owned 154,482 shares in the company, valued at approximately $1,836,790.98. This represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Arvinas Trading Up 3.3%

Shares of NASDAQ ARVN traded up $0.38 during mid-day trading on Wednesday, hitting $11.82. The company had a trading volume of 559,743 shares, compared to its average volume of 759,739. The company has a market capitalization of $759.13 million, a price-to-earnings ratio of -14.59 and a beta of 1.88. Arvinas, Inc. has a 1 year low of $5.90 and a 1 year high of $19.40. The stock’s 50-day moving average price is $12.40 and its 200-day moving average price is $10.32.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ARVN. Wells Fargo & Company decreased their price target on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Barclays increased their target price on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. BTIG Research raised their price target on shares of Arvinas from $10.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Wedbush restated a “neutral” rating and set a $9.00 price target on shares of Arvinas in a research report on Thursday, November 6th. Ten research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $13.12.

Institutional Trading of Arvinas

A number of hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC increased its stake in Arvinas by 7.2% in the fourth quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock valued at $176,000 after acquiring an additional 993 shares during the last quarter. Intech Investment Management LLC lifted its stake in Arvinas by 3.6% during the third quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock worth $278,000 after purchasing an additional 1,125 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Arvinas by 4.3% in the 4th quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock worth $401,000 after purchasing an additional 1,381 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Arvinas by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after purchasing an additional 2,122 shares during the last quarter. Finally, Oxford Asset Management LLP raised its holdings in shares of Arvinas by 15.5% during the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after buying an additional 2,242 shares in the last quarter. 95.19% of the stock is owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.